Key result
Dilated-phase HCM is linked to ~3.6-fold higher IL-6 levels than nonobstructive disease.
Why the study?
Patients with idiopathic hypertrophic cardiomyopathy may deteriorate to dilated-phase hypertrophic cardiomyopathy, and the pathogenesis of this progression was unknown.
Cohort (n=59)
No
Answers are grounded in this paper and cite their sources.
We examined the plasma levels of soluble Fas (sFas) or Fas ligand (sFas-L), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in patients with idiopathic nonobstructive (HNCM) and dilated-phase (DHCM) hypertrophic cardiomyopathy. Patients with idiopathic hypertrophic cardiomyopathy (HCM) may deteriorate to DHCM and the pathogenesis is unknown. The levels of these plasma cytokines were measured by ELISA and echocardiography was performed in 38 HNCM and 11 DHCM patients, and 10 normal subjects. The follow-up period was three years. In HNCM, TNF-alpha (43.3 +/- 45.2 versus 16.9 +/- 4.3 pg/mL) and IL-6 (65.1 +/- 86.4 versus 4.0 +/- 2.1 pg/mL) were slightly higher compared to normal subjects and sFas (3.7 +/- 1.2 versus 2.1 +/- 0.7 ng/mL) increased significantly. sFas (3.9 +/- 1.8), TNF-alpha (79.3 +/- 72.4), and IL-6 (234.1 +/- 135.2) in DHCM were significantly increased and only IL-6 was significantly different from HNCM. sFas-L (0.18 +/- 0.08 versus 0.25 +/- 0.05 ng/mL) in HNCM was significantly decreased, and the decrease was marked in DHCM (0.05 +/- 0.02). In HNCM, TNF-alpha was negatively correlated with fractional shortening (r = -0.432, P = 0.0062) or positively with IL-6 (r = 0.665, P < 0.0001), while sFas-L was negatively correlated with IL-6 (r = -0.580, P < 0.0001). DHCM with high sFas had significantly higher cumulative incidences of worsening heart failure. The Fas/Fas-L system and proinflammatory cytokines may play an important role in the status of HCM and its progression to DHCM.
No takes yet. Share an insight, caveat, or question.
Zen et al. (2005) conducted a cohort in Idiopathic hypertrophic cardiomyopathy (nonobstructive and dilated-phase) (n=59). Dilated-phase hypertrophic cardiomyopathy (DHCM) and circulating apoptosis mediators/cytokines (sFas, sFas-L, TNF-alpha, IL-6) vs. Hypertrophic nonobstructive cardiomyopathy (HNCM) and normal subjects was evaluated on Plasma Interleukin-6 (IL-6) levels (pg/mL) comparing DHCM vs HNCM (p=<0.05). Patients with dilated-phase hypertrophic cardiomyopathy had significantly higher IL-6 (234.1 vs 65.1 pg/mL) and lower sFas-L (0.05 vs 0.18 ng/mL) than nonobstructive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: